Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
67
resultados
Última actualización
20/03/2026 [07:28:00]
Resultados 50 a 67 de 67
Resumen de: KR20260011952A
본 발명은 알츠하이머 자가진단 키트에 관한 것으로서 Sample pad에 전개액을 뿌리면 흡수되며 용액이 이동하며 항체를 이동시키고 5분 이내의 짧은 검사 시간 후에 Membrane pad의 control line과 test line 에서 발색 신호가 나타나게 함으로써, 개인이 집에서 진단하기에 어렵다는 문제점을 해소하도록 함으로써 기존의 뇌척수액을 추출해 검사해야 하며 과정이 복잡하므로 개인이 집에서 진단하기에 어려움 문제점을 해소 하도록 한 것이다.즉 본 발명은, 알츠하이머 진단을 위한 ELISA 테스트에 있어서 Strip에서 전개액을 가하는 부분으로, 이 부분에 전개액을 뿌리면 흡수되며 용액이 이동할 수 있게 흡수가 용이한 패드로 구성한 Sample pad, 바이오마커와 결합할 수 있고 시각적 태그(금나노입자)가 붙어있는 항체가 고정되어 있어 전개액이 흐르면 같이 이동할 수 있게 항체를 손상 없이 고정시키고, 전개액이 도달했을 때 잘 이동시킬 수 있는 패드로 구성한 Conjugate pad, control line과 test line의 항원 또는 항체가 부착되어 있어 발색 신호를 알 수 있게 시각적 태그가 결합되어 있고, 아밀로이드 베타와 결합할 수 있는 항체가 용이하게 이동할 수 있는 패드로 구성한 Membrane pad, 이동한 전개액과 반응하지 않은 항체 등이 흡수될 수 있게 용액 흡�
Resumen de: CN121378475A
The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.
Resumen de: CN121385316A
The invention discloses an immunosensor for detecting neurofilament light chain protein of Alzheimer's disease and a preparation method of the immunosensor, and belongs to the technical field of biological detection.The immunosensor for detecting the neurofilament light chain protein of Alzheimer's disease is prepared by taking a glassy carbon electrode (GCE) modified with a Ce2Sn2O7-NH2 (at) Au-Ab1 conjugate and a Pd (at) ZIF-8-NH2 (at) Au-Ab2 conjugate as a working electrode. According to the invention, ultrahigh-sensitivity, high-specificity and high-stability detection of the Alzheimer's disease biomarker NFL is realized, and technical support is provided for early diagnosis and large-scale screening of Alzheimer's disease.
Resumen de: WO2024235879A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Resumen de: CN121385288A
The invention relates to an Alzheimer's disease marker detection kit and application thereof. The kit comprises a first reagent for enriching brain-derived exosomes and a second reagent for detecting the concentration of Alzheimer's disease markers, the first reagent comprises microspheres coupled with a first antibody and a first buffer solution, and the first antibody comprises a LINGO1 antibody and/or an OMGP antibody; the second reagent comprises microspheres coupled with a second antibody and a second buffer solution, and the second antibody comprises a pTau217 antibody and/or a pTau181 antibody. The kit provided by the invention can highly enrich brain-derived exosomes, and can detect Alzheimer's disease markers (a Tau217 antibody and/or a pTau181 antibody) with high sensitivity and high specificity so as to assist in diagnosing AD (Alzheimer's disease).
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: US20260023086A1
The present invention is directed to a protein aggregation assay, and methods of use thereof.
Resumen de: WO2026018204A1
Provided herein is a method of detecting an amyloid peptide in a patient sample, including exposing the patient sample to a binding reagent in the presence of an assay binding buffer, thereby immunoprecipitating the amyloid peptide; washing the immunoprecipitated amyloid peptide; eluting the washed, immunoprecipitated amyloid peptide, thereby generating free amyloid peptide; and analyzing the free amyloid peptide with a mass spectrometer.
Resumen de: WO2026019699A1
The present disclosure is directed to engineered cells designed to sense tau and to express one or more proteins in response to this binding event. In addition, the cells and associated methods of use can detect, treat, and recapitulate the symptoms of Alzheimer's disease. The engineered cells can regulate expression of neuronal growth factors and anti-inflammatory proteins to address neurodegeneration and neuroinflammation, respectively.
Resumen de: WO2026020153A1
Composition and methods for treating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Angelman's Syndrome (AS), the compositions specifically including antisense oligonucleotides (ASOs) containing thiomorpholino nucleotides configured to inhibit ribosomal frameshifting of paternally expressed gene 10 (PEG 10) mRNA during translation, thereby inhibiting the formation of the long form gag-pol protein.
Resumen de: WO2026019970A1
The disclosure relates to compositions and methods for diagnosing, stratifying, prognosing, treating and preventing and cognitive impairment, including Alzheimer's Disease, based on the identification of disease-associated metabolic transitions.
Resumen de: CN114981452A
The invention relates to a molecular marker for silent period of Alzheimer's disease. And methods of using the same for diagnosing the silent phase of Alzheimer's disease in a subject, classifying the silent phase of Alzheimer's disease in a subject into different levels of silent phase, predicting the progression of a silent phase of Alzheimer's disease in a subject, and determining an individualized treatment process for a subject suffering from a silent phase of Alzheimer's disease. It also relates to a computer system comprising a trained machine learning algorithm for diagnosing the silent period of Alzheimer's disease in a subject.
Resumen de: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: CN120731367A
The present invention relates to a method for determining the level of PAM and/or its homoisomers and/or fragments thereof in a bodily fluid or tissue sample using an assay comprising at least one binding agent for conformational epitopes of PAM, and to the use of said method for diagnostic purposes.
Resumen de: CN121362579A
The invention relates to the technical field of biological medicine, in particular to a nano tube based on fluorescently-labeled small peptide and application of the nano tube, the nano tube is a self-assembled nano tube and is specifically formed by electrostatic adsorption of FAM/heme-KD oligopeptide and a KL-7 polypeptide nano tube; the FAM/heme-KD polypeptide is an FAM/heme-KLVFFAED-NH2 peptide fragment, and the KL-7 polypeptide is an Ac-KLVFFAL-NH2 peptide fragment, and the FAM/heme-KD polypeptide is a KLVFFAED-NH2 peptide fragment. The nanotube based on the fluorescently-labeled small peptide shows excellent sensitivity, rapid response capability, specific recognition and affinity to the Abeta40 aggregate, and can be used for detecting the Abeta40 aggregate, detecting fibrosis of the Abeta40 aggregate, screening an Abeta40 aggregate inhibitor and diagnosing Alzheimer's disease.
Resumen de: KR20260008880A
본 발명은 유전자 CpG 부위의 메틸화 수준을 검출함으로써, 알츠하이머병 치매로의 진행 위험성을 예측하기 위한 조성물, 키트 및 방법에 관한 것이다.
Nº publicación: KR20260009358A 19/01/2026
Solicitante:
노젤라프게엠베하
Resumen de: WO2024235879A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
BOPI
Sede Electrónica
